BMRNBioMarin Pharmaceutical Inc.

$12B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$596M+14.8% YoY

Gross Profit

$461M77.3% margin

Operating Income

$62M10.5% margin

Net Income

$51M8.5% margin

EPS (Diluted)

$0.26

QoQ Revenue Growth

+11.0%

Cash Flow

Operating Cash Flow

-$74M

Free Cash Flow

-$99M

Stock-Based Comp.

$54M

Balance Sheet

Total Assets

$6.4B

Total Liabilities

$1.8B

Stockholders' Equity

$4.7B

Cash & Equivalents

$580M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$596M	$519M	+14.8%
Gross Profit	$461M	$402M	+14.6%
Operating Income	$62M	$137M	-54.6%
Net Income	$51M	$121M	-57.9%

Revenue Segments

Product

$586M56%

Enzyme Product

$448M43%

Royalty And Other

$10M1%

BMRN Q1 2023 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena